“Why The Nasdaq is Really Crashing in 2026 (Sell Now or Buy the Dip?)”
AI summary · Eli Lilly is still expensive at 65 times free cash flow and a forward P/E of 39; despite great returns on capital and 39% sales growth to a record near $1,450, justifying the price needs much larger potential earnings, which even with GLP-1 drugs looks difficult, so the speaker would probably wait much longer before buying.
Eli Lilly, the pharmaceutical company responsible for popular weight-loss treatments, hit a record high of nearly $1,450 per share. Its sales jumped by a massive 39% in the last quarter.